GSK

About our products

Our leading products:

♦ Augmentin   ♦ Amoxil

♦ Panadol       ♦ Ventolin

♦ Ampiclox     ♦ Betnovate

♦ Calpol          ♦ Zantac

♦ Septran

Pakistan Overview

GlaxoSmithKline Pakistan Limited was created on January 1st 2002 through the merger of SmithKline and French of Pakistan Limited, Beecham Pakistan (Private) Limited and Glaxo Wellcome (Pakistan) Limited- standing today as the largest pharmaceutical company in Pakistan

As a leading international pharmaceutical company we make a real difference to global healthcare and specifically to the developing world. We believe this is both an ethical imperative and key to business success. Companies that respond sensitively and with commitment by changing their business practices to address such challenges will be the leaders of the future. GSK Pakistan operates mainly in two industry segments: Pharmaceuticals (prescription drugs and vaccines) and consumer healthcare (over-the-counter- medicines, oral care and nutritional care).

GSK leads the industry in value, volume and prescription market shares. We are proud of our consistency and stability in sales, profits and growth. Some of our key brands include Augmentin, Panadol, Seretide, Betnovate, Zantac and Calpol in medicine and renowned consumer healthcare brands include Horlicks, Aquafresh, Macleans and ENO.

In addition, we are also deeply involved with our communities and undertake various Corporate Social Responsibility initiatives including working with the National Commission for Human

Development (NCHD) for whom we were one of the largest corporate donors. We consider it our responsibility to nurture the environment we operate in and persevere to extend our support to our community in every possible way. GSK participates in year round charitable activities which include organizing medical camps, supporting welfare organizations and donating to/sponsoring various developmental concerns and hospitals. Furthermore, GSK maintains strong partnerships with non-government organizations such as Concern for Children, which is also extremely involved in the design, implementation and replication of models for the sustainable development of children with specific emphasis on primary healthcare and education.

Corporate Functions

M. Salman Burney - Managing Director

Dr. Muzaffar Iqbal - Technical Director, Global Manufacturing and Supply

Pervaiz Iqbal Awan - Director Sales

Maqbool Ur Rahman - Director Sales

Erum Shakir Rahim - Director Marketing & Business Development

Javed Ahmedjee - Director Finance, IT & Logistics

Shahid M. Qureshi - Director Legal, Corporate Affairs, IR, Admin and Regulatory

Fariha K. Salahuddin - Head of Human Resource and Organisational Development

Dr. Ahmad Atif Mirza - Director Medical Affairs and R&D

Sohail Matin - Country Manager, Consumer Healthcare

Head Office

35- Dockyard Road, West Wharf, Karachi- 74000.Telephones: 2315478-82, 2316071-73 and 2315101-08Fax: 2314898 and 2311122

Sites & Locations

Karachi

35- Dockyard Road, West Wharf, Karachi- 74000.Telephones: 111-GSK-PAK (111-475-725)Fax: 2314898 and 2311122

94, Deh Landhi,Karachi.Telephones: 5015040-44Fax: 5015515

F/268, S.I.T.E,Near Labour Square,Karachi-75700Telephones: 2599999 Fax: 2572613 and 2570360

B/63, Estate Avenue S.I.T.E,Karachi.Telephones: 2561200-7Fax: 2564797

Lahore

19.5 km, Ferozepur Road,P.O.Box No. 244,Lahore.Telephones: 5811931-35Fax: 5820821

Cordeiro House,Plot No. 27, Kot Lakhpat Industrial Estate,Kot Lakhpat, LahoreTelephones: 5111061-64 and 5111066-69Fax: 5111065 and 5111067

Mission Statement

Excited by the constant search for innovation, we at GSK undertake our quest with the enthusiasm of entrepreneurs. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency.

Our mission is to improve the quality of human life by enabling people to do more, feel better and live longer.

Quality is at the heart of everything we do- from the discovery of a molecule to the development of a medicine.

ho we are

GlaxoSmithKline, Pakistan (GSKP) Limited is the largest research-based pharmaceutical company in the country and the second largest in the world. We have been represented in Pakistan since 1955, which puts us in a great position to make a difference to our community and promote good corporate citizenship.

We strive to be valued corporate citizens no matter where we do business. We have always shown strong commitment and support for public health and awareness initiatives and have championed many social causes. In the face of growing adversity, especially in the developing world, we have responded through three main channels: preferential pricing (vaccines and anti-virals being offered on non profit basis/discounts), research and development and community investment. The Group's strong commitment to the community is reflected in various charitable

projects in Pakistan, and around the world. Our relationship with our various communities is something we are very proud of as individuals and as an organization.

According to the Guardians Giving List: GSK was at 6th place before any other pharmaceutical company, with the highest over all gift in kind quantity and the third highest over all cash donation of £61 million in 2006.

GSKP was also awarded the prestigious Management Association of Pakistan (MAP) award for which nominations are based on independent evaluation of quality of management practices including corporate governance, marketing planning, production, R&D and corporate social responsibility and also financial performance. Awards are given in two categories - Business & Industrial and Financial and GSKP won the overall Corporate Excellence Award in the Business & Industrial category by obtaining the highest score across all sectors in 2007.

What we are Doing

Global Community Partnerships is GSK's charitable program that works with partner organizations in the developed and developing worlds to help improve the health and education of under-served communities. It does so through the traditional areas of funding, product donations and expertise while also aiming to build strategic partnerships that result in mutual benefit for all involved. GSK's global community investment activities in 2006 were valued at £302 million, equivalent to 3.9% of pre-tax profits and GSK contributed £22 million of life saving antibiotics and other medicines to support disaster relief efforts in 99 countries in 2006 as well.

Sensodyne for sensitive teeth

If you have sensitive teeth, you'll probably experience occasional discomfort or pain when eating or drinking cold, hot or acidic food, or when you brush your teeth. Now you can enjoy food with Sensodyne!

People who have sensitive teeth often miss out on many of life's pleasures unnecessarily, such as ice-cream and cold drinks. Regular brushing with Sensodyne helps relieve the pain of sensitive teeth, allowing you to enjoy the food and drink you've been avoiding.

Equally importantly, it helps you maintain strong teeth and healthy gums. It gives you breath fresh too after brushing.

Sensodyne is available in the following varieties in Pakistan:

Sensodyne Original & Sensodyne Fluoride

Sensodyne's unique Original formula with Sensogard™:

Works progressively to relieve the pain of sensitive teeth. With regular twice daily use, builds long term protection. Cleans thoroughly and polishes brightly. Leaves your mouth feeling really clean and fresh.

It is available in 50 ml & 75 ml.

For more information, visit our     Sensodyne website .

Horlicks

Horlicks, also known as 'The Great Family Nourisher', is a nutritional drink containing wheat, malted barley and milk. It is fortified with iron and eight essential vitamins. One serving of Horlicks contains twice the calcium content of a glass of fresh milk. Along with other vital nutrients, calcium helps build strong bones and teeth in children and also helps in maintaining healthy bones in adults.

It is nourishing, easy to digest and is very easy to use; Take 3-4 teaspoonfuls (27 gm) of Horlicks malted food drink in a mug. Add water to form a paste. Fill with hot or cold milk-or water and stir briskly.

In Pakistan, the beverage is available in malt flavor and has two varieties of jars ranging from 200gm to 400gm.

The key market of Horlicks is India where, along with the traditional formula there is also a special preparation for breastfeeding mothers and children aged between one and three.

For more information, visit our     Horlicks website .

Quick links:

GSK Corporate Website Report

GSK Annual Reports Careers at GSK Pakistan

Iodex

Iodex is an antirheumatic ointment - which is to be rubbed into the skin to relieve pain. Iodex should be used externally and has numerous advantages for conditions that require a soothing and penetrating balm. It is used for the symptomatic relief of muscular pain and stiffness (including rheumatic pains, backache, lumbago, sciatica, fibrositis, muscular aches, sprains and strains, painful bruising) and chilblains where the skin is unbroken.

In Pakistan, Iodex is available in a glass jar. The brand is for external use only.

Direction for use: (Adults and children over 4 years of age) Where the skin is unbroken, rub in gently until the color disappears. 3 0r 4 applications a day are recommended. Bandages employed over this ointment, should be light and loose, not tight and air excluding.

Caution: Keep out of the reach of children.

Eno

If you often feel discomfort or pain in the upper chest or abdomen, chances are that you have suffer from indigestion. The most obvious symptom to look out for is a feeling of being bloated or very full. Many people mistake indigestion for an ailment resulting from overeating, but this is a myth because you can get indigestion even if you eat very little. Quick relief is all that you want when suffering from indigestion and this is exactly what ENO provides you. As soon as you get that bloated feeling after a meal, have a glass of ENO and you will feel the difference immediately.

ENO is a refreshing, bubbly drink which comes in three variants- Original, Lemon and orange In Pakistan ENO is available in bottles and sachets.

Aquafresh Toothpaste

Good oral hygiene is important for all the family. While many toothpastes may provide a level of protection, only Aquafresh toothpaste has the three stripes which give triple protection to your family's teeth and gums. And they make brushing more fun for everyone!

Aquafresh has three coloured stripes which provide protection in three ways:

Red stripe - FIGHTS PLAQUEWhite stripe - FIGHTS DECAYBlue stripe - FRESHENS BREATH

The brand is available in two variants, which are:

a) Fresh & Mintyb) Mild & Minty

Two sizes are available: in 50 ml & 75 ml.

Aquafresh Mouthwash

Aquafresh Mouthwash freshens breath, acting in the places toothbrushes may miss. They protect teeth & gums with a special fluoride formula that helps to fight decay. They also clean mouth leaving a fresh clean feeling.

GSK facts

GSK dedicated to R&D for 80 years Cost of bringing a medicine to market: $800 million (Rs 4.8 billion) Average length of time to discover new drug: 10-15 years 5 out of every 10,000 compounds investigated reach clinical trial phase and only 1 of those gets

approved for patient use. GSK has industry's most extensive portfolio of R&D projects for diseases affecting developing

countries

GSK Pakistan overview

GSK Pakistan Limited was created on January 1st 2000 through the merger of SmithKline Beecham (Pakistan) and Glaxo Wellcome (Pakistan) and it stands as the largest pharmaceutical company in Pakistan today.

GSK leads the industry in value, volume and prescription market shares. We are proud of our consistency and stability in sales, profits and growth. Some of our key brands include Augmentin, Panadol, Seretide, Betnovate, Zantac and Calpol in medicine and renowned consumer healthcare brands include Horlicks, Aquafresh, Macleans and ENO.

Performance with integrity

We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency

GSK aims to build competencies by offering a fulfilling and healthy work environment where our employees can grow and develop. We seek talented individuals who can produce results in a competitive environment where self development is an essential part of the learning process in order to achieve maximum potential.

Spirit of GSK

We undertake our quest with the enthusiasm of entrepreneurs, excited by the constant search for innovation. We value performance achieved with integrity. We will attain success as a world class global leader with each and every one of our people contributing with passion and an unmatched sense of urgency

Performance with IntegrityDelivering on promises with organisational and individual trustworthiness

People with PassionInspiring, motivating, and enabling people to do their best work

Innovation & EntrepreneurshipCreating and sustaining competitive advantage through well-executed ingenuity

Sense of UrgencyCreating a focused, agile, productive and fast-learning organisation

Everyone Committed, Everyone ContributingEnabling, encouraging, and allowing all employees the opportunity to make meaningful contributions and succeed on merit

Accountability for AchievementSetting, communicating, and committing to the critical few clear expectations. Superior performance matters and will be rewarded

Alignment with GSK InterestsOperating as "one team, in single-minded pursuit of our mission", reflecting a common spirit and integrated strategies

Develop Self and OthersLearning continuously and developing professional potential and ability. Leaders act as teachers, coaches, and champions of development, creating career-long learning across the organisation

Diversity

At GSK, we are committed to creating an inclusive and interactive work environment for our employees, customers, and stakeholders. Diversity has become a core part of the solution to and a way forward for many of the strategic objectives that face our business today. It helps improve business performance because the better we understand and respond to the diverse needs of our employees the more we are able to create an environment where understanding and acceptance is prevalent.

For employees and potential recruits, our comprehensive procedures ensure that we hire a diverse workforce and provide development opportunities to retain the diverse talent. Why?

Because we believe our employees are our human capital and our biggest assets which is why we strive to meet their expectations.

For customers, our awareness and appreciation of diversity promotes our ability to appreciate and react to varied customer requirements - as a result we build confidence levels and long term relationships with our customers.

For stakeholders, our focus on diversity facilitates our involvement with varied communities and improves client relations. Diverse employees add value because they can better understand diverse markets. Diversity also influences investors, both private and institutional with regard to ethical policies. GSK is dedicated to establishing and maintaining relationships with minority groups, non governmental organizations and diverse communities.

Learning at GSK

We believe self development is everyone's personal responsibility and we ensure that employees have at their disposal, various tools and opportunities to realise their development plans.

Development of soft skills

On-the-job training

This is in the form of rotation and assignments. GSK is committed to making a considerable investment into your development in terms of practical and interpersonal growth, through on-the-job training.

Learning sessions

These are sessions where GSK employees enrol for courses focused on the development of technical and management skills. Our goal is to offer powerful and effective intervention with an organized infrastructure that opens a fast and efficient channel for training staff with materials that are updated periodically as learning needs change.

Library

There is a wide collection of books and other information sources on various subjects available at our in house library with the goal of supporting the development needs of GlaxoSmithKline employees. Topics include best management practice, marketing, communications, current affairs and other organization development topics.

Self-paced learning

Mylearning is an internet based portal where you can enrol into courses. It includes learning courses and resources that are conveyed by electronic means and is self paced whereby

employees can develop at their own pace. It permits the instant and continuous transfer of information and instruction to thousands of staff members at the same time.

Sales training

GSK is constantly striving to develop people both professionally and personally.

To achieve this goal, an Initial Training Course (ITC) is held for the newly inducted field force.

Objectives of the ITC are:

1. To help new inductees understand the complete product portfolio2. To understand the mission, vision and spirit of GSK.

The new inductees are trained on:

1. Business and microbiology foundation. 2. Product knowledge. 3. Excellence in Selling (EIS) competencies which include excelling and territory management.

Once the business and microbiology foundation and product knowledge session is complete, the inductees are assessed.

HR & OD Consultants

We welcome contact with consultants who have an expertise on Leadership Development, executive coaching and Organizational Effectiveness with a business perspective that can be aligned closely to our mission.

Recruiters, head hunters, HR vendors and consultants are invited to submit their profiles to [email protected] or contact (021) 2202710.

"We are a business-focused, partner based organization with an effective model of growth and development for employees to progress towards leadership roles."

Our mission and strategy

The pharmaceutical industry is experiencing a time of unprecedented challenge. Patent expiries, regulatory issues and increased pressures from healthcare providers have combined to create an environment where our sector is associated with lower growth and higher risk.

We are addressing these challenges through three key strategic priorities that we believe will transform GSK into a company that delivers more growth, less risk and an improved financial performance.

Three strategic priorities

In 2008, we established the following three strategic priorities:

Grow a diversified global business Deliver more products of value Simplify the operating model

Announcing GSK's 2009 Annual Results, CEO Andrew Witty said, "Our strategy is delivering and I believe that GSK is now moving to a position where we can deliver our goal of long-term sustainable financial performance. 2009 saw GSK return to sales growth and I am confident of our prospects on 201

Grow a diversifiedglobal business

We are diversifying our business to create a more balanced product portfolio and move away from a reliance on traditional white pill/ western markets. We are investing in key growth areas such as Emerging Markets, Japan, Vaccines and our Consumer Healthcare business.

We expect to generate future sales growth by strengthening our core pharmaceuticals business and supplementing it with increased investment in growth areas such as vaccines, biopharmaceuticals and

consumer healthcare.

We are also seeking to unlock the geographic potential of our businesses, particularly in emerging markets and Japan.

We have made good progress on this priority during 2009, and we believe there remain many opportunities for GSK to diversify further.

Our plans

Drive growth in the pharmaceutical business in our core markets Deliver our ambitious vaccines forecast Fulfil the potential of emerging markets Expand our business in Japan Grow the Consumer Healthcare business

Find out more about these plans plus our measures and progress

"It's important that we generate more growth with less risk."

InvestorsAnnual Report 2009

Go to the Annual Report 2009

Deliver

We are transforming R&D.

Deliver more products of value

Simplify

We are changing the way we work.

Simplify the operating model

Quick links

Corporate responsibility About GSK Our Board

Grow a diversified global business

Our measures and progress

Performance of core pharmaceuticals and vaccines businesses

The core pharmaceuticals and vaccines businesses delivered sales of £19.1 billion and grew 5% in 2009. This excludes genericised products, Avandia and influenza products. Including pandemic products, sales were £20.9 billion, up 12% for 2009

Diversification of sales

Sales from white pill/western markets fell from 36% of turnover in 2008 to 30% in 2009

Contribution of Emerging Markets to our overallsales and growth

Sales in the Emerging Markets pharmaceutical business grew 20% to nearly £3 billion in 2009, now representing 10% of Group turnover

We completed 10 bolt-on acquisitions in 2009 In November 2009 we launched Viiv Healthcare, a joint ventre with Pfizer aimed at delovering

advances in treatment and care for people living with HIV

Growth of Consumer Healthcare market share

Consumer Healthcare market share gains were delivered in the OTC and Oral healthcare businesses, but share declined in Nutritional healthcare

Consumer Healthcare sales grew 7% to £4.7 billion, with growth in all categories: OTC up 8%; Oral healthcare up 7%; Nutritional healthcare up 3%

In July 2009, we completed the aquisition of Stiefel Laboratories, a global leader in dermatology

Expansion of Japanese business

Sales reached £1.6 billion in 2009, up 22%, driven by Adoair and Relenza Products launched in the last three years contributed around £260 million sales in 2009

Build biopharmaceutical portfolio

Arzerra was launched in the USA, a positive opinion was received for Prolia and positive phase III data was announced for Benlysta in 2009

Around 17% of our pipeline now comprises biopharmaceutical assets

Deliver moreproducts of value

We aim to sustain an industry-leading pipeline of products, ensuring that they demonstrate value for healthcare providers. Our R&D strategy is built around focussing on the best science, diversifying through externalisation of research, and improving the returns on investment.

As we move towards a more diversified business we will concentrate on developing a higher volume of mid-size products for more clearly-defined patient populations. This will help develop a lower risk portfolio which is not dependent on the performance of one or two large products.

Positive steps have already been taken, with 30 late-stage assets currently in our pharmaceuticals and vaccines pipeline. Our objective is to sustain this throughput of products over the long-term.

Our plans

Focus on the best science Diversify through externalisation Re-personalise R&D Focus on return on investment

Find out more about these plans plus our measures and progress

"To be successful in the healthcare marketplace in the next few years its all going to be about delivering value."

Deliver more products of value

Our measures and progress

Contribution to sales of new products

New pharmaceutical products launched since 2007 contributed sales of £1.3 billion, or £2.1 billion including H1N1 pandemic vaccine

Number of reimbursable product approvals and filings

We received 12 product approvals and completed 11 new filings in 2009. In the last three years we have obtained more FDA approvals for new molecular entities and vaccines than any other company

Sustaining late-stage pipeline

We maintained around 30 assets in phase III and registration, with five new programmes entering phase III during 2009

Enhanced R&D productivity and increased externalisation for Drug Discovery

Our projected rate of return based on investment made in our late stage pipeline and expected future long-term sales performance is around 11%. Our long-term goal is to improve our rate of return for R&D to around 14%

We have ‘externalised’ approximately 30% of our discovery research with 47 external partners

Simplify theoperating model

GSK is a large and complex organisation. We are transforming our operational model to reduce complexities, improve efficiency and reduce costs.

Our global restructuring programme is a vital catalyst of our strategy.

We believe it will radically change our business model giving us the capability to support a more diverse, growing business that is also expected to be more profitable in the long-term.

Our plans

Evolve our commercial model Re-shape manufacturing Streamline our processes Reduce working capital

Find out more about these plans plus our measures and progress

"By simplifying our operating model I want to make it easier for our employees to make decisions."

implify the operating model

Our measures and progress

Delivery of major restructuring programme

Annual cost savings of £1 billion have already been achieved. The programme has been expanded again to deliver annual savings of £2.2 billion by 2012

Our products

Prescription medicines

Medicines prescribed bya healthcare professional

Consumer healthcare

Dental health products, over-the-counter medicines and nutritional drinks

Vaccines

Vaccines that prevent disease and illness

ViiV Healthcare

Advances in treatment andcare for HIV communities

Feature product

Purple Haze

Ribena is one of the most popular brands in the UK. But how is it produced? Altogether only about 1000 people are involved from growing the fruit to producing the squeezed blackcurrant juice.

Find out more about how Ribena is made

Reducing weight with alli

GSK markets alli, a weight-loss aid. alli is for adults who are overweight with a BMI of 28 or over, want to lose weight and who understand the importance of sensible eating when they’re trying to lose weight.

Find out more about alli

Prescription medicines

Our prescription medicines include treatments for a wide range of conditions such as infections, depression, skin conditions, asthma, heart and circulatory disease and cancer.

Here you will find the Patient Information Leaflets or Prescribing Information for our medicines. Please note that this information is often specific to a country or region and is not intended to replace the advice of a qualified doctor.

Products are in various stages of approval around the world and may not be available in every country.

We also offer Material Safety Data Sheets (MSDSs) for GSK products marketed in the US and Safety Data Sheets (SDSs) for GSK products marketed in the UK are available in PDF format.

Vaccines

We market over 25 vaccines worldwide to prevent potentially life-threatening or crippling illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis.

The majority of our vaccine R&D activities are conducted at GlaxoSmithKline Biologicals in Rixensart, Belgium. Over 1300 of our research scientists are devoted to developing new vaccines and more cost-effective and convenient combination vaccines to prevent infections that cause serious medical problems worldwide.

We are also targeting therapeutic vaccines that may prevent relapse in cancer patients. The strength of our vaccine pipeline will provide opportunities for us to consistently deliver new vaccines for many years to come.

Here you will find the Patient Information Leaflets or Prescribing Information for our vaccines. Please note that this information is often specific to a country or region and is not intended to replace the advice of a qualified doctor.

Products are in various stages of approval around the world and may not be available in every country.

Consumer Healthcare

We bring dental health products, over-the-counter medicines and nutritional drinks to millions of people. Many of our brands, such as Panadol, Aquafresh, Lucozade and Nicorette/Niquitin are familiar around the world.

The consumer healthcare business brings an added dynamic dimension to our company, but, as for all of our products, the driving force behind our consumer healthcare business is science. With four dedicated consumer healthcare R&D centres and consumer healthcare regulatory affairs, the business takes scientific innovation as seriously as marketing excellence and offers leading-edge capability in both.

The following list includes our major consumer products. Some of these products may not be available in your country.

Material Safety Data Sheets (MSDSs) for GSK products marketed in the US and Safety Data Sheets (SDSs) for GSK products marketed in the UK are available in PDF format.